Clinomics Ahead of IPO "Challenging the 200 Trillion Early Diagnosis Market with Genome 2.0"

Next-Generation Genome Technology 'Multi-Omics' for Early Diagnosis and Big Data Platform Development
First Large-Scale Genome Project Participation in Korea... "Challenging the 200 Trillion Won Global Market"

Kim Byung-chul, CEO of Clinomics, is explaining the business strategy at a press conference held on the 16th in Yeouido, Yeongdeungpo-gu, Seoul.

[Asia Economy Reporter Minwoo Lee] Clinomics, a precision diagnostics specialist company, has announced its intention to go public. The company aims to open the early diagnosis market through genome-based early diagnosis and a bio big data platform.

On the 16th, Kim Byung-chul, CEO of Clinomics, held a press conference in Yeouido, Yeongdeungpo-gu, Seoul, to announce these plans. The company intends to target the early diagnosis market using core technologies such as 'multi-omics' and liquid biopsy.

Multi-omics is a technology that intelligently predicts and diagnoses various diseases by comprehensively reflecting the human body's condition, which changes according to genetic factors as well as environment and lifestyle. Since it analyzes a combination of various tests including epigenome, genome, proteome, metabolome, and transcriptome, it can be applied to almost all underlying diseases. Moreover, because big data is analyzed using artificial intelligence, it enables early diagnosis and monitoring tests that go beyond existing precision diagnostics.

Already, after introducing this technology, a blood-based test to predict depression and suicide risk was conducted. While the accuracy of the test using simple blood tests was 86.7%, the accuracy of the test applying multi-omics rose significantly to 94.3%. The strategy is to develop early diagnosis products for the genome 2.0 era that surpass current diagnostic levels using multi-omics technology. Clinical trials for early diagnosis products for stress and depression are planned to be completed by 2022, with full commercialization expected around 2023. CEO Kim stated, "Multi-omics is a next-generation genome technology called 'Genome Technology 2.0' and is a core bio technology for future healthcare innovation."

Since its establishment in 2011, Clinomics has been researching and developing core technologies such as multi-omics technology for prognosis, prediction, and diagnosis of diseases, aiming to be the world's number one in genome technology. In 2016, the company participated in Korea's first large-scale genome project. Together with the Ulsan National Institute of Science and Technology, it has been building a genome database (DB) of 10,000 Koreans until last year. Since 2017, it has commercialized 10 types of healthcare products and 10 precision medical services. Major products include ▲ multi-omics product groups that analyze medical, clinical information, and lifestyle big data to predict diseases and physical characteristics ▲ liquid biopsy product groups that build cancer-related early diagnosis, companion diagnostics, and monitoring solutions using a non-invasive high-speed liquid biopsy platform.

To date, the company has carried out 24 government projects worth over 10 billion KRW cumulatively, and its key researchers have published 52 Science Citation Index (SCI)-level papers, demonstrating top domestic research and development capabilities. It currently holds a total of 121 patents. Clinomics operates a Bio Big Data Center (BBC) in Osong, Chungcheongbuk-do, and plans to expand its computer center for ultra-large big data processing to secure analysis speeds twice as fast as the current level by 2030.

CEO Kim emphasized, "We are challenging the global market worth approximately 200 trillion KRW centered on multi-omics and liquid biopsy. By commercializing a pipeline focused on multi-omics, we will achieve the number one position in the global precision medicine market and secure a leading company status."

Meanwhile, Clinomics' total number of shares offered in the public offering is 1,972,323 shares. The expected price range is 10,900 to 13,900 KRW per share. The public offering funds are expected to be between 21.4 billion and 27.4 billion KRW. Demand forecasting will be conducted on the 17th and 18th to finalize the offering price, followed by a general subscription on the 23rd and 24th. The listing is scheduled for early next month, with Daishin Securities as the lead underwriter.

This content was produced with the assistance of AI translation services.